InvestSMART

Medical Developments International Limited (ASX:MVP)

ALERT: Price-sensitive ASX Announcement for MVP
Current share price for MVP : $0.410 -0.215 (-34.40%)+
Announcement
Release
10 Oct 2025 9:04AM
Price at Release
$0.625
Full Release
download
Summary
Medical Developments International Limited (MVP) released its Appendix 4C and Quarterly Activity Report for the quarter ending 30 September 2025. The company reported a cash balance of $16.1 million, with significant improvements in cash from operating activities. The group revenue for Q1 FY26 stood at $10.9 million, marking a $1.9 million increase compared to the previous corresponding period, driven largely by the growth of Penthrox sales. Penthrox volumes in the Australian hospital segment increased by 26%, and European demand grew by 12%. The company is focusing on strategic initiatives to enhance Penthrox's market penetration, including its newly approved paediatric label in select European markets. Despite seasonal softness in the Respiratory segment, MVP has managed to offset increased costs through pricing strategies. Looking forward, MVP aims to boost investment in growth initiatives and expects these efforts to lead to improved long-term financial performance, despite a projected softer underlying EBIT for FY26.
Key Points
  • Cash balance at 30 September 2025 was $16.1 million.
  • Group revenue for Q1 FY26 was $10.9 million, up $1.9 million from the prior corresponding period.
  • Penthrox volumes increased by 26% in the Australian hospital segment.
  • European in-market demand for Penthrox grew by 12%.
  • Successful implementation of pricing strategies to mitigate higher costs from US tariffs.
  • Strategic focus on embedding Penthrox as a standard of care.
  • Continued investment in growth initiatives expected to yield long-term financial benefits.
  • Approval of Penthrox's paediatric label in select European markets.
  • Expectations of softer Underlying EBIT in FY26 compared to the previous year.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.